Webcast to be held Monday, September 23, at 8:00 a.m. ET ...

Ces experts du National Institute of Allergy and Infectious Diseases (NIAID/NIH) ont établi avec de grands instituts américains, tout un réseau de recherche sur la préparation aux pandémies. Ce réseau ...

Les antioxydants présents dans les algues ont déjà trouvé des utilisations dans la cicatrisation, le traitement des MICI, de l’arthrite, plus rarement dans les maladies cognitives ou neurologiques.

L'herpès est causé par une infection par l'un des deux types de virus de l'herpès simplex (HSV). Environ deux tiers des personnes (67 %) âgées de 0 à 49 ans dans le monde sont atteintes du HSV-1, ...

Cette étude de biologistes de l’Institut Riken (Japon) aboutit à une découverte importante : les antigènes alimentaires comme les protéines du lait contribuent à empêcher les tumeurs de se développer ...

“We have seen the profound impact this medicine has had for GA patients in the U.S. and remain committed to expanding access to this crucial treatment, focusing on serving unmet patient needs in the U ...

Pending authorization of the Omicron KP.2-adapted vaccine by the EC, both the Omicron KP.2-adapted vaccine and the Omicron JN.1-adapted vaccine will be available across the EU, though availability ...

(NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of ...

This new European approval reinforces Ipsen’s commitment to advancing medical innovations to treat people living with rare cholestatic liver diseases ...

Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...

In accordance with Section 3 of the Articles of Association of Orion Corporation, 213,285 A shares have been converted into 213,285 B shares. The conversion has been entered into the Trade Register on ...